Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL

Key Points

• Janus Henderson Group cut its Ocular Therapeutix stake by 98.4% in the first quarter, selling 4.16 million shares and retaining 68,500 shares valued at approximately $581,000. Institutional investors collectively own 59.21% of the company.
• Ocular Therapeutix reported a quarterly loss of $0.35 per share, beating analyst expectations of a $0.40 loss, while revenue of $13.47 million slightly exceeded estimates. However, revenue declined marginally year over year and the company remains deeply unprofitable.
• Analyst sentiment is broadly positive, with an average rating of “Moderate Buy” and a consensus price target of $25.75, despite recent sell and strong-sell downgrades from some firms.

Janus Henderson Group PLC trimmed its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 98.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 68,500 shares of the biopharmaceutical company's stock after selling 4,160,702 shares during the period. Janus Henderson Group PLC's holdings in Ocular Therapeutix were worth $581,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC grew its position in Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,242 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Ocular Therapeutix during the fourth quarter worth about $31,000. Hilton Head Capital Partners LLC raised its position in Ocular Therapeutix by 30.4% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,053 shares during the last quarter. Atlas Capital Advisors Inc. bought a new position in Ocular Therapeutix during the 4th quarter worth approximately $61,000. Finally, KBC Group NV bought a new stake in Ocular Therapeutix during the fourth quarter valued at $78,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Trading Up 0.5%

NASDAQ:OCUL opened at $9.24 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -6.51 and a beta of 0.93. Ocular Therapeutix, Inc. has a 52 week low of $6.23 and a 52 week high of $16.44. The firm has a 50-day moving average price of $9.16 and a two-hundred day moving average price of $9.08.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. The company had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.Ocular Therapeutix's quarterly revenue was down .1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.39) earnings per share. On average, equities analysts expect that Ocular Therapeutix, Inc. will post -1.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on OCUL. Weiss Ratings reissued a "sell (d-)" rating on shares of Ocular Therapeutix in a research note on Friday, July 17th. Needham & Company LLC reissued a "buy" rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Wall Street Zen upgraded Ocular Therapeutix from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Zacks Research downgraded shares of Ocular Therapeutix from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Ocular Therapeutix has an average rating of "Moderate Buy" and a consensus target price of $25.75.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the business's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the transaction, the insider owned 2,597,170 shares of the company's stock, valued at approximately $21,296,794. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 28,999 shares of company stock valued at $237,792 over the last 90 days. 3.10% of the stock is currently owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source